BLAINJECTIONINJECTABLE
Approved
Dec 2021
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 26m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REZVOGLAR is a biosimilar insulin glargine approved by the FDA in December 2021, manufactured by Eli Lilly and Company. It is a long-acting basal insulin analog used to treat type 1 and type 2 diabetes mellitus. The drug works by mimicking endogenous insulin to regulate blood glucose levels in patients requiring insulin therapy.
Peak
Product is in peak commercial phase with established market presence; teams are likely focused on defending market share against competitive insulin products and optimizing existing infrastructure.
Mechanism of Action
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
REZVOGLAR offers career opportunities primarily in commercial and market access functions rather than clinical development. Working on this product means focusing on execution, payer negotiations, field force enablement, and competitive differentiation in a mature insulin market.
Brand ManagerField Sales Representative
Worked on REZVOGLAR at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.